Norvēģija -
norvēģu -
Statens legemiddelverk
methylprednisolone orion 16 mg
orion corporation orion pharma, espoo - metylprednisolon - tablett - 16 mg
Norvēģija -
norvēģu -
Statens legemiddelverk
saizen 8 mg/ ml
merck serono s.p.a (1) - somatropin - injeksjonsvæske, oppløsning - 8 mg/ ml
Norvēģija -
norvēģu -
Statens legemiddelverk
saizen 5.83 mg/ ml
merck serono s.p.a (1) - somatropin - injeksjonsvæske, oppløsning - 5.83 mg/ ml
Norvēģija -
norvēģu -
Statens legemiddelverk
xalatan 50 mikrog/ ml
upjohn eesv - latanoprost - Øyedråper, oppløsning - 50 mikrog/ ml
Eiropas Savienība -
norvēģu -
EMA (European Medicines Agency)
insulin aspart sanofi
sanofi winthrop industrie - insulin aspart - sukkersyke - legemidler som brukes i diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Eiropas Savienība -
norvēģu -
EMA (European Medicines Agency)
kirsty (previously kixelle)
biosimilar collaborations ireland limited - insulin aspart - sukkersyke - legemidler som brukes i diabetes - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Eiropas Savienība -
norvēģu -
EMA (European Medicines Agency)
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Øyemidler - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Eiropas Savienība -
norvēģu -
EMA (European Medicines Agency)
truvelog mix 30
sanofi winthrop industrie - insulin aspart - sukkersyke - legemidler som brukes i diabetes - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.
Eiropas Savienība -
norvēģu -
EMA (European Medicines Agency)
inpremzia
baxter holding b.v. - insulin human (rdna) - sukkersyke - legemidler som brukes i diabetes - inpremzia is indicated for the treatment of diabetes mellitus.
Eiropas Savienība -
norvēģu -
EMA (European Medicines Agency)
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).